Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
A Prospective Cohort Study of Telitacicept Versus Conventional Immunosuppressive Agents in Primary Sjögren's Disease With Interstitial Lung Disease
This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This is a prospective, open-label, single-center cohort study to evaluate the real-world effectiveness of Telitacicept compared with conventional immunosuppressive therapy in patients with primary Sjögren's disease associated interstitial lung disease. A total of 60 patients with confirmed interstitial lung disease by high-resolution computed tomography will be enrolled and allocated into two cohorts based on the treatment regimen selected by their treating physician according to clinical indications and patient preference: one cohort receiving Telitacicept 160 mg subcutaneously once weekly and the other receiving conventional immunosuppressive agents.
Treatment effectiveness will be evaluated over 24 weeks. The primary outcome is the change from baseline in forced vital capacity percent predicted (FVC% predicted) at Week 24. Secondary assessments include DLCO% predicted, total lung capacity, HRCT changes quantified using the Warrick score, KL-6, ESSDAI. Changes in B-cell subsets and related biomarkers will be explored for associations with pulmonary outcomes.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Jing Ning
- Numer telefonu: +86 18292023082
- E-mail: ningjing9548@163.com
Kopia zapasowa kontaktu do badania
- Nazwa: Yuan Jia
- Numer telefonu: +86 15601066669
- E-mail: jiayuan1023@bjmu.edu.cn
Lokalizacje studiów
-
-
-
Beijing, Chiny
- Rekrutacyjny
- Department of Rheumatology and Immunology, Peking University People's Hospital
-
Kontakt:
- Jing Ning
- Numer telefonu: +86 18292023082
- E-mail: ningjing9548@163.com
-
Kontakt:
- Jia Yuan
- Numer telefonu: +86 15601066669
- E-mail: jiayuan1023@bjmu.edu.cn
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
The study population will consist of 60 adult patients with primary Sjögren's disease and HRCT-confirmed interstitial lung disease, enrolled and allocated to treatment groups based on real-world clinical practice.
Opis
Inclusion Criteria:
- Age 18 to 70 years, male or female.
- Diagnosis of primary Sjögren's Syndrome meeting the 2016 ACR/EULAR classification criteria.
- Confirmed diagnosis of Interstitial Lung Disease by High-Resolution Computed Tomography (HRCT).
- Stable doses of corticosteroids and immunosuppressants (e.g., mycophenolate mofetil) for at least 1 week prior to enrollment.
- Willing and able to provide written informed consent
Exclusion Criteria:
-
Allergy: Known allergy or hypersensitivity to Telitacicept or any of its excipients.
-
Concomitant Autoimmune Diseases: Diagnosis of other systemic autoimmune diseases besides Sjögren's Syndrome, such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Mixed Connective Tissue Disease (MCTD), or ANCA-associated vasculitis. (Note: Secondary Sjögren's Syndrome is not excluded on this basis alone, but the primary condition must be considered).
-
Laboratory Abnormalities (at Screening):
Hematology:
Hemoglobin (Hb) < 85 g/L. White Blood Cell count (WBC) < 3.0 × 10^9/L. Neutrophil count (NEUT) < 1.5 × 10^9/L. Platelet count (PLT) < 80 × 10^9/L.
Liver Function:
Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 2.5 × the upper limit of normal (ULN).
Total bilirubin (TBIL) > 1.5 × ULN.
Kidney Function:
Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m². Or serum creatinine (Cr) > 1.5 × ULN.
-
Significant Organ Diseases or Comorbidities:
Cardiovascular: Myocardial infarction or unstable angina within the past 6 months; uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg); pulmonary arterial hypertension with evidence of right heart failure.
Respiratory: Presence of other significant lung diseases (e.g., COPD, asthma, pulmonary embolism, active pulmonary tuberculosis).
Gastrointestinal: Active peptic ulcer, gastrointestinal bleeding, or pancreatitis.
Malignancy: History of any malignancy within the past 5 years (excluding successfully treated basal cell carcinoma of the skin or in-situ cervical carcinoma).
Psychiatric: Severe mental illness (e.g., severe depression, schizophrenia) or cognitive impairment that may interfere with compliance.
-
Prior/Concomitant Medications:
Use of rituximab, belimumab, TNF inhibitors (e.g., etanercept, adalimumab), or ther biologic agents (e.g., IL-6, IL-17, IL-23 inhibitors) within 3 months prior to screening.
Participation in another interventional clinical trial (receiving investigational drug or device) within 4 weeks prior to screening.
-
Active Infection:
Presence of an active infection requiring systemic anti-infective treatment at screening.
Active tuberculosis (positive T-SPOT.TB or TST with chest X-ray/CT findings suggestive of active disease).
Positive HIV antibody. Positive Hepatitis B surface antigen (HBsAg), or positive Hepatitis B core antibody (HBcAb) with detectable HBV DNA.
Positive Hepatitis C antibody with detectable HCV RNA.
-
Special Populations:
Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use highly effective contraceptive methods from screening until at least 3 months after the last dose of study drug.
Patients planning to undergo major surgery during the study period.
-
Other Situations:
Inability to cooperate with pulmonary function tests (e.g., due to severe cognitive impairment or dyspnea).
Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study (e.g., poor compliance, inability to understand study procedures).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
The telitacicept group
Patients in the treatment group will receive subcutaneous telitacicept 160 mg once weekly for 24 weeks, in addition to their background therapy (hydroxychloroquine and/or conventional immunosuppressive agents), and will be followed up regularly. |
The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks. Conventional treatment with methylprednisolone (≤ 40 mg/day) and other immunosuppressive agents (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, tripterygium glycosides, methotrexate, and sulfasalazine). Treatment restrictions: The use of immunosuppressants was limited to a maximum of three agents throughout the 24-week period, and dose adjustments from baseline were restricted to within 30%. |
|
The control group
Participants in the control group will receive background therapy (hydroxychloroquine and/or conventional immunosuppressive agents) alone for 24 weeks, and will be followed up regularly according to the same schedule. |
Conventional treatment with methylprednisolone (≤ 40 mg/day) and other immunosuppressive agents (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, tripterygium glycosides, methotrexate, and sulfasalazine). Treatment restrictions: The use of immunosuppressants was limited to a maximum of three agents throughout the 24-week period, and dose adjustments from baseline were restricted to within 30%. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Forced Vital Capacity Percent Predicted at Week 24
Ramy czasowe: At baseline and at week 12,24
|
FVC will be measured using standardized pulmonary function testing and expressed as the percentage of the predicted value. The outcome will be calculated as Week 24 FVC% predicted minus baseline FVC% predicted. The adjusted between-group difference will be estimated between the telitacicept and conventional-treatment cohorts. |
At baseline and at week 12,24
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Diffusing Capacity for Carbon Monoxide Percent Predicted at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24
|
The outcome will be calculated as Week 24 DLCO% predicted minus baseline DLCO% predicted. |
Baseline, Week 12, and Week 24
|
|
Change From Baseline in Total Lung Capacity at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24
|
Total lung capacity will be measured by standardized pulmonary function testing. Both the observed value and percent predicted, where available, will be recorded. |
Baseline, Week 12, and Week 24
|
|
Change From Baseline in HRCT Warrick Score at Week 24
Ramy czasowe: Baseline and Week 24
|
HRCT abnormalities will be assessed using the Warrick scoring system. The severity score ranges from 0 to 15 and is based on five abnormalities: ground-glass opacity (1 point), irregular pleural margins (2 points), septal or subpleural lines (3 points), honeycombing (4 points), and subpleural cysts (5 points). For each abnormality, extent is scored according to the number of bronchopulmonary segments involved: 1-3 segments (1 point), 4-9 segments (2 points), and more than 9 segments (3 points), giving a total extent score of 0-15. The Warrick total score is the sum of severity and extent scores and ranges from 0 to 30, with higher scores indicating greater ILD involvement. |
Baseline and Week 24
|
|
Change From Baseline in Serum Krebs von den Lungen-6 at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24
|
Serum Krebs von den Lungen-6 (KL-6) concentration will be measured as a biomarker associated with interstitial lung disease activity and severity. |
Baseline, Week 12, and Week 24
|
|
Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index at Week 24
Ramy czasowe: Baseline, Week 12, and Week 24
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) will be assessed at each specified visit. The outcome is Week 24 ESSDAI minus baseline ESSDAI. |
Baseline, Week 12, and Week 24
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Changes in Peripheral B-cell Subsets and Related Biomarkers
Ramy czasowe: Baseline, Week 12, and Week 24
|
Changes from baseline in total B cells, B-cell subsets, immunoglobulins, and soluble CD25 will be evaluated. Associations between immunologic changes and changes in FVC% predicted, DLCO% predicted, Warrick score, and KL-6 will be explored. |
Baseline, Week 12, and Week 24
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Yuan Jia, Peking University Institute of Rheuamotology and Immunology
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu mięśniowo-szkieletowego
- Choroby jamy ustnej
- Choroby Stomatognatyczne
- Artretyzm
- Choroby stawów
- Choroby reumatyczne
- Choroby tkanki łącznej
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Choroby Układu Oddechowego
- Choroby płuc
- Choroby oczu
- Zapalenie stawów, reumatoidalne
- Kserostomia
- Choroby gruczołów ślinowych
- Zespoły suchego oka
- Choroby aparatu łzowego
- Choroby skóry i tkanki łącznej
- Zespół Sjogrena
- Choroby płuc, śródmiąższowe
- Telitacicept
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 2026-Telitacicept-SjD-ILD
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .